Progenics Pharmaceuticals, Opposition. (Nasdaq: PGNX) at the moment presented the draw up and reasoning of an ceaseless occasion 1 proof of its prostate-specific membrane antigen antibody cure-all bound (PSMA ADC) analysis at the 2010 Reference Tryst of the Dweller Brotherhood of Clinical Oncology (ASCO). That stage 1 examination is assessing the security, tolerability and inaugural clinical movement of with time crescendo doses of PSMA ADC in patients with increasing, metastatic, hormone-refractory prostatic sign mass one-time taxane chemotherapy. The results would be euphemistic pre-owned to ascertain dosing representing supplementary judgement in stage 2 clinical investigation.
“First-in-human time 1 trying out of prostate-specific membrane antigen antibody cure-all conjugated (PSMA ADC) in taxane-refractory endocrine someone”
The bill, entitled, “First-in-human juncture 1 trial run of prostate-specific membrane antigen antibody treatment united (PSMA ADC) in taxane-refractory endocrine crab” purposefulness be presented on Mon, June 7 from 8:00 a.m. to 12:00 p.m. Median Term. The “Trials in Advance” Placard Sitting is premeditated to further connectedness amidst simultaneous and dormant investigators nearby unbroken clinical trials and provides qualifications of the study bum an continuing checking light testing draw up and ingress of subjects (outcomes text or results are tabu from delivery).